Overactive Bladder Treatment Market Size & Share Report - 2032

Overactive Bladder Treatment Market - By Condition Type (Neurogenic, Idiopathic], Treatment Type (Drug Therapy [Anticholinergic, Beta-3 Adrenoceptor Agonist], Botox Treatment, Neuromodulation), Age Group (31-50, 51-60) – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of overactive bladder

3.2.1.2&nbsp;&nbsp;&nbsp;Growing aging population

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing research investments and activities

3.2.1.4&nbsp;&nbsp;&nbsp;Growing awareness for early diagnosis and treatment

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Adverse effects associated with medications and treatment

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porters analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Condition Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Neurogenic bladder overactivity

5.3&nbsp;&nbsp;&nbsp; Idiopathic bladder overactivity

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Drug therapy

6.2.1&nbsp;&nbsp;&nbsp; Anticholinergics

6.2.2&nbsp;&nbsp;&nbsp; Beta-3 adrenoceptor agonists

6.3&nbsp;&nbsp;&nbsp; Botox treatment

6.4&nbsp;&nbsp;&nbsp; Neuromodulation

6.5&nbsp;&nbsp;&nbsp; Other treatment types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; 18-30

7.3&nbsp;&nbsp;&nbsp; 31-50

7.4&nbsp;&nbsp;&nbsp; 51-60

7.5&nbsp;&nbsp;&nbsp; 60 above

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.2&nbsp;&nbsp;&nbsp; South Africa

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; AbbVie Inc.

9.2&nbsp;&nbsp;&nbsp; Astellas Pharma Inc.

9.3&nbsp;&nbsp;&nbsp; Axonics, Inc.

9.4&nbsp;&nbsp;&nbsp; BlueWind Medical

9.5&nbsp;&nbsp;&nbsp; Cipla Ltd.

9.6&nbsp;&nbsp;&nbsp; Endo International plc

9.7&nbsp;&nbsp;&nbsp; Laborie

9.8&nbsp;&nbsp;&nbsp; Lupin Ltd.

9.9&nbsp;&nbsp;&nbsp; Medtronic plc

9.10&nbsp;&nbsp;&nbsp; Merck &amp; Co.

9.11&nbsp;&nbsp;&nbsp; Pfizer Inc.

9.12&nbsp;&nbsp;&nbsp; Sumitomo Pharma America, Inc. (Urovant Sciences)

9.13&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd.

9.14&nbsp;&nbsp;&nbsp; Viatris Inc.

9.15&nbsp;&nbsp;&nbsp; Zydus Lifesciences Ltd. 
&nbsp;

Overactive Bladder Treatment Market

Get a free sample of this report